Breast cancer: New concepts in classification;Carcinoma de mama: Novos conceitos na classificação

Revista Brasileira de Ginecologia e Obstetricia

Volumn 30, Issue 1, 2008, Pages 42-47

  Vieira, Daniella Serafin Couto ^a   Dufloth, Rozany Mucha ^a,e   Schmitt, Fernando Carlos Lander ^b,c   Zeferino, Luiz Carlos ^d  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e Condomínio Residencial Solar de Francavilla ^*  (United States)

Author keywords

Analysis methods; Breast neoplasms classification; Breast neoplasms diagnosis; Oligonucleotide array sequence; Prognosis; Proteomics

Indexed keywords

BREAST TUMOR; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; REVIEW;

BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS;

EID: 42149158797     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032008000100008     Document Type: Review

References (60)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
2. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40(18):2667-75.
3. Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. Lyon: WHO/ IARC; 2003.
4. Ministério da Saúde. Secretaria de Atenção à Saúde. Instituto Nacional do Câncer. Coordenaç ão de Prevenção e Vigilância. Estimativa 2006: incidência de câncer no Brasil [texto na Internet]. Rio de Janeiro: INCA; 2005 [citado 2006 Set 6 ]. Disponível em: http://www.inca.gov.br/ estimativa/2006/versaofinal.pdf
5. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.
6. Eisenberg ALA. Sobrevida de cinco anos para pacientes com carcinoma ductal infiltrante de mama sem comprometimento de linfonodos axilares. Coorte Hospitalar, 1992-1996. Rio de Janeiro: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz; 2004.
7. Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-Jauffret E. Basal and luminal breast cancers: basic or luminous? Int J Oncol. 2004;25(2):249-58.
8. Böcker W, Moll R, Poremba C, Holland R, van Diest PJ, Dervan P, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002;82(6):737-46.
9. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
10. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat. 1998;51(3):195-208.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-10.
12. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59(3):225-31.
13. van de Vijver MR, He YD, Van't Verr LJ, Dai H, Hart AA, Voskuil, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
14. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005;18(1):26-35.
15. Kristensen VN, Sorlie T, Geisler J, Langerod A, Yoshimura N, Karesen R, et al. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. Clin Cancer Res. 2005;11(2 Pt 2):878s-83s.
16. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23.
17. Kronenwett U, Ploner A, Zetterberg A, Bergh J, Hall P, Auer G, et al. Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol Bimarkers Prev. 2006;15(9):1630-5.
18. Sasco AJ. Breast cancer and the environment. Horm Res. 2003;60 Suppl 3:50.
19. Bertucci F, Birnbaum D, Gonçalves A. Proteomics of breast carcinoma: principles and potential clinical applications. Mol Cell Proteomics. 2006;5(10):1772-86.
20. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74.
21. Simon R, Mirlacher M, Sauter G. Tissue microarrays in cancer diagnosis. Expert Rev Mol Diagn 2003;3(4):421-30.
22. Santos PM, Teixeira MC, Sá-Correa I. A análise proteómica quantitativa na revelação de mecanismos de resposta a stresse químico em microrganismos. Lisboa: Boletim de Biotecnologia; 2004.
23. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127.
24. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999;26(4 Suppl 12):71-7.
25. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling tumor of specimens. Nature Med. 1998;4(7):844-7.
26. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 2003;55(1):20-9.
27. Kallioniemi O, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001;10(7):657-62.
28. Hidalgo A, Piña P, Guerrero G, Lazos M, Salcedo M. A simple method for the construction of small format tissue arrays. J Clin Pathol. 2003;56(2):144-6.
29. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-5.
30. Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol. 2004;13(1):1-8.
31. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
32. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74.
33. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet. 2000;9(20):2981-91.
34. Bertucci F, Bernard K, Loriod B, Chang YC, Granjeaud S, Birnbaum D, et al. Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Hum Mol Genet. 1999;8(9):1715-22.
35. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 2000;60(8):2232-8.
36. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999;96(16):9212-7.
37. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(1 Suppl 1):S53-67.
38. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157(5):1467-72.
39. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. P63, cytokeratin 5, and P-cadherin: three markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447(4):688-94.
40. Paredes J, Lopes N, Milanezi F, Schmitt FC. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007;450(1):73-80.
41. Paredes J, Albergaria A, Carvalho S, Schmitt FC. Basal-like breast carcinomas: identification by P-cadherin, P63 and EGFR basal cytokeratins expression. Appl Cancer Res. 2006;26(2):41-55.
42. Dufloth RM. Carcinoma de mama hereditário em mulheres brasileiras: mutações dos genes de BRCA1 e BRCA2, polimorfismos dos genes de reparo do DNA e caracterização imunoistoquímica pela técnica de tissue microarray [tese]. Campinas: Universidade Estadual de Campinas; 2004.
43. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-53.
44. Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristic in cancer prognosis? Eur J Cancer. 2007;43(4):745-51.
45. Bennett IC, Gattas M, Teh BT. The management of familial breast cancer. Breast. 2000;9(5):247-63.
46. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003;9(10 Pt 1):3606-14.
47. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
48. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-92.
49. Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist. 2004;9(1):13-24.
50. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-89.
51. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 1997;350(9078):638-9.
52. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88(2):265-75.
53. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26(14):2126-32.
54. Billis A, Vassallo J. Patologia diagnóstica de tumores. Campinas: Impressão Digital do Brasil; 2004.
55. Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 2006;14(1):103-8.
56. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TMA: breast cancer TNM classification for treatment decision-making and research. Breast. 2006;15(1):3-8.
57. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PD, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12(1):27-34.
58. Castilho L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol. 2007;15(7):1007-12.
59. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer. 2007;14(2):163-73.
60. Costa C, Soares R, Schmitt F. Angiogenesis: now and then. APMIS. 2004;112(7-8):402-12.